tradingkey.logo

Bluejay Diagnostics Inc

BJDX
0.706USD
-0.039-5.27%
收盤 12/24, 13:00美東報價延遲15分鐘
1.16M總市值
虧損本益比TTM

Bluejay Diagnostics Inc

0.706
-0.039-5.27%

關於 Bluejay Diagnostics Inc 公司

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc簡介

公司代碼BJDX
公司名稱Bluejay Diagnostics Inc
上市日期Nov 10, 2021
CEODey (Neil)
員工數量7
證券類型Ordinary Share
年結日Nov 10
公司地址360 Massachusetts Avenue, Suite 203
城市ACTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01720
電話19786310152
網址https://bluejaydx.com/
公司代碼BJDX
上市日期Nov 10, 2021
CEODey (Neil)

Bluejay Diagnostics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--

收入明細

FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月20日 週四
更新時間: 11月20日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
其他
84.80%
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
其他
84.80%
股東類型
持股股東
佔比
Corporation
9.67%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
1.86%
Hedge Fund
0.63%
Individual Investor
0.03%
其他
84.36%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
21
107.69K
6.48%
--
2025Q3
22
107.69K
7.87%
-5.14K
2025Q2
22
108.63K
1.16%
+96.42K
2025Q1
23
12.21K
4.22%
-11.19K
2024Q4
24
12.14K
4.03%
-17.82K
2024Q3
26
29.96K
1.04%
+23.88K
2024Q2
26
6.08K
2.15%
+5.00K
2024Q1
24
1.08K
7.93%
+549.00
2023Q4
24
499.00
2.34%
+441.00
2023Q3
25
58.00
1.55%
+36.00
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Sabby Management, LLC
96.03K
6.43%
+96.03K
--
Jun 30, 2025
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
Tower Research Capital LLC
2.27K
0.15%
+533.00
+30.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.20K
0.28%
--
--
Aug 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
公告日期
類型
比率
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
Jul 21, 2023
Merger
20→1
查看更多

常見問題

Bluejay Diagnostics Inc的前五大股東是誰?

Bluejay Diagnostics Inc的前五大股東如下:
Sabby Management, LLC
持有股份:96.03K
佔總股份比例:6.43%。
Armistice Capital LLC
持有股份:6.95K
佔總股份比例:0.47%。
Tower Research Capital LLC
持有股份:2.27K
佔總股份比例:0.15%。
Geode Capital Management, L.L.C.
持有股份:4.20K
佔總股份比例:0.28%。
Lana Management & Business Research International LLC
持有股份:511.00
佔總股份比例:0.03%。

Bluejay Diagnostics Inc的前三大股東類型是什麼?

Bluejay Diagnostics Inc 的前三大股東類型分別是:
Intracoastal Capital, L.L.C.
DRW Securities, LLC
Sabby Management, LLC

有多少機構持有Bluejay Diagnostics Inc(BJDX)的股份?

截至2025Q4,共有21家機構持有Bluejay Diagnostics Inc的股份,合計持有的股份價值約為107.69K,占公司總股份的6.48% 。與2025Q3相比,機構持股有所增加,增幅為-1.39%。

哪個業務部門對Bluejay Diagnostics Inc的收入貢獻最大?

在FY2023,--業務部門對Bluejay Diagnostics Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI